Detalles de la búsqueda
1.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582092
2.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139274
3.
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat
; 205(3): 589-598, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38456970
4.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587643
5.
Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer.
Int J Mol Sci
; 25(7)2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38612751
6.
Top advances of the year: Breast cancer.
Cancer
; 129(12): 1791-1794, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37014257
7.
Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain.
Int J Mol Sci
; 24(15)2023 Jul 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37569408
8.
Can we cure oligometastatic disease? A practical point of view.
Curr Opin Oncol
; 32(6): 568-574, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32925203
9.
CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation.
Virchows Arch
; 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38713384
10.
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial.
EClinicalMedicine
; 71: 102520, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38638399
11.
Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response.
Front Immunol
; 14: 1227766, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37600765
12.
A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer.
Front Oncol
; 13: 1048242, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37496662
13.
Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Cancers (Basel)
; 15(7)2023 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37046661
14.
Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature.
Front Oncol
; 13: 1158981, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37213307
15.
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Neuro Oncol
; 25(1): 157-166, 2023 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35639825
16.
Oligometastatic Disease: When Stage IV Breast Cancer Could Be "Cured".
Cancers (Basel)
; 14(21)2022 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36358646
17.
Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era.
Am Soc Clin Oncol Educ Book
; 42: 1-11, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35671434
18.
Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases.
Cancers (Basel)
; 14(5)2022 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35267459
19.
Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study.
Int J Infect Dis
; 123: 97-103, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35987472
20.
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments.
Eur J Cancer
; 166: 229-239, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35316750